Lenalidomide-Induced Interstitial Pneumonitis in a Patient with Multiple Myeloma: A Case Report
Archives of Medical Reports · 30.09.2025 · 2 (5) · 13-15
DOI: 10.26524/amr.2025.5.4 ↗Kurz gefasst
Fallbericht in der Zeitschrift Archives of Medical Reports, online erschienen am 30.09.2025. Verfasst von Dhasha Neha und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Lenalidomide, a second-generation immunomodulatory agent used in the treatment of multiple myeloma (MM), is generally well tolerated. Pulmonary toxicity, though rare, can present as interstitial pneumonitis, leading to diagnostic challenges. We describe a case of a 67-year-old man with relapsed MM who developed progressive dyspnea and cough after initiation of lenalidomide. High-resolution chest CT revealed bilateral ground-glass opacities suggestive of interstitial lung disease. Infectious, autoimmune, and cardiogenic causes were excluded. Symptoms and imaging abnormalities resolved upon discontinuation of lenalidomide and initiation of corticosteroids. This case illustrates the need for awareness of lenalidomide-induced pneumonitis as a potential but reversible adverse event in MM patients, emphasizing early recognition and drug withdrawal.
Zitieren
APA
Neha, D., & Twaheih, A. M. M. A. (2025). Lenalidomide-Induced Interstitial Pneumonitis in a Patient with Multiple Myeloma: A Case Report. Archives of Medical Reports, 2(5), 13-15. https://doi.org/10.26524/amr.2025.5.4
Vancouver
Neha D, Twaheih AMMA. Lenalidomide-Induced Interstitial Pneumonitis in a Patient with Multiple Myeloma: A Case Report. Archives of Medical Reports. 2025;2(5):13-15. doi:10.26524/amr.2025.5.4
BibTeX
@article{Neha2025,
author = {Neha, Dhasha and Twaheih, Ali Mahmoud Mansour Al},
title = {Lenalidomide-Induced Interstitial Pneumonitis in a Patient with Multiple Myeloma: A Case Report},
journal = {Archives of Medical Reports},
year = {2025},
volume = {2},
number = {5},
pages = {13--15},
doi = {10.26524/amr.2025.5.4}
}
EUVIMED